AMITRIPTYLINE HYDROCHLORIDE tablet, film coated

Nchi: Marekani

Lugha: Kiingereza

Chanzo: NLM (National Library of Medicine)

Viambatanisho vya kazi:

Amitriptyline Hydrochloride (UNII: 26LUD4JO9K) (Amitriptyline - UNII:1806D8D52K)

Inapatikana kutoka:

Mylan Pharmaceuticals Inc.

INN (Jina la Kimataifa):

Amitriptyline Hydrochloride

Tungo:

Amitriptyline Hydrochloride 10 mg

Njia ya uendeshaji:

ORAL

Dawa ya aina:

PRESCRIPTION DRUG

Matibabu dalili:

For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than are other depressive states. Amitriptyline hydrochloride tablets are contraindicated in patients who have shown prior hypersensitivity to it. It should not be given concomitantly with monoamine oxidase inhibitors. Hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. When it is desired to replace a monoamine oxidase inhibitor with amitriptyline hydrochloride, a minimum of 14 days should be allowed to elapse after the former is discontinued. Amitriptyline hydrochloride should then be initiated cautiously with gradual increase in dosage until optimum response is achieved. Amitriptyline hydrochloride should not be given with cisapride due to the potential for increased QT interval and increased risk for arrhythmia. This drug is not recommended for use during the acute recovery phase following myocardi

Bidhaa muhtasari:

Amitriptyline Hydrochloride Tablets, USP are available containing either 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, or 150 mg of amitriptyline hydrochloride, USP. The 10 mg tablets are white, film-coated, round, unscored tablets debossed with M77 on one side of the tablet and blank on the other side. They are available as follows: NDC 0378-2610-01 bottles of 100 tablets NDC 0378-2610-10 bottles of 1000 tablets The 25 mg tablets are light green, film-coated, round, unscored tablets debossed with M over 51 on one side of the tablet and blank on the other side. They are available as follows: NDC 0378-2625-01 bottles of 100 tablets NDC 0378-2625-10 bottles of 1000 tablets The 50 mg tablets are brown, film-coated, round, unscored tablets debossed with M over 36 on one side of the tablet and blank on the other side. They are available as follows: NDC 0378-2650-01 bottles of 100 tablets NDC 0378-2650-10 bottles of 1000 tablets The 75 mg tablets are blue, film-coated, round, unscored tablets debossed with M over 37 on one side of the tablet and blank on the other side. They are available as follows: NDC 0378-2675-93 bottles of 30 tablets NDC 0378-2675-01 bottles of 100 tablets The 100 mg tablets are orange, film-coated, round, unscored tablets debossed with M over 38 on one side of the tablet and blank on the other side. They are available as follows: NDC 0378-2685-93 bottles of 30 tablets NDC 0378-2685-01 bottles of 100 tablets The 150 mg tablets are flesh, film-coated, capsule-shaped, unscored tablets debossed with M 39 on one side of the tablet and blank on the other side. They are available as follows: NDC 0378-2695-93 bottles of 30 tablets NDC 0378-2695-01 bottles of 100 tablets Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from light. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.

Idhini hali ya:

Abbreviated New Drug Application

Taarifa za kipeperushi

AMITRIPTYLINE HYDROCHLORIDE- AMITRIPTYLINE HYDROCHLORIDE TABLET, FILM
COATED
Mylan Pharmaceuticals Inc.
----------
MEDICATION GUIDE
Antidepressant Medicines, Depression and Other Serious Mental
Illnesses, and Suicidal Thoughts or
Actions
Read the Medication Guide that comes with your or your family
member’s antidepressant medicine. This
Medication Guide is only about the risk of suicidal thoughts and
actions with antidepressant medicines.
Talk to your, or your family member’s, healthcare provider about:
•
all risks and benefits of treatment with antidepressant medicines
•
all treatment choices for depression or other serious mental illness
What is the most important information I should know about
antidepressant medicines, depression and
other serious mental illnesses, and suicidal thoughts or actions?
1.
Antidepressant medicines may increase suicidal thoughts or actions in
some children, teenagers, and
young adults within the first few months of treatment.
2.
Depression and other serious mental illnesses are the most important
causes of suicidal thoughts and
actions. Some people may have a particularly high risk of having
suicidal thoughts or actions. These
include people who have (or have a family history of) bipolar illness
(also called manic-depressive
illness) or suicidal thoughts or actions.
3.
How can I watch for and try to prevent suicidal thoughts and actions
in myself or a family
member?
•
Pay close attention to any changes, especially sudden changes, in
mood, behaviors, thoughts,
or feelings. This is very important when an antidepressant medicine is
started or when the
dose is changed.
•
Call the healthcare provider right away to report new or sudden
changes in mood, behavior,
thoughts, or feelings.
•
Keep all follow-up visits with the healthcare provider as scheduled.
Call the healthcare
provider between visits as needed, especially if you have concerns
about symptoms.
Call a healthcare provider right away if you or your family member has
any of the following
symptoms, especially if they

Tabia za bidhaa

AMITRIPTYLINE HYDROCHLORIDE- AMITRIPTYLINE HYDROCHLORIDE TABLET, FILM
COATED
MYLAN PHARMACEUTICALS INC.
----------
SUICIDALITY AND ANTIDEPRESSANT DRUGS
ANTIDEPRESSANTS INCREASED THE RISK COMPARED TO PLACEBO OF SUICIDAL
THINKING AND BEHAVIOR
(SUICIDALITY) IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS IN SHORT-TERM
STUDIES OF MAJOR
DEPRESSIVE DISORDER (MDD) AND OTHER PSYCHIATRIC DISORDERS. ANYONE
CONSIDERING THE USE OF
AMITRIPTYLINE OR ANY OTHER ANTIDEPRESSANT IN A CHILD, ADOLESCENT, OR
YOUNG ADULT MUST BALANCE
THIS RISK WITH THE CLINICAL NEED. SHORT-TERM STUDIES DID NOT SHOW AN
INCREASE IN THE RISK OF
SUICIDALITY WITH ANTIDEPRESSANTS COMPARED TO PLACEBO IN ADULTS BEYOND
AGE 24; THERE WAS A
REDUCTION IN RISK WITH ANTIDEPRESSANTS COMPARED TO PLACEBO IN ADULTS
AGED 65 AND OLDER.
DEPRESSION AND CERTAIN OTHER PSYCHIATRIC DISORDERS ARE THEMSELVES
ASSOCIATED WITH
INCREASES IN THE RISK OF SUICIDE. PATIENTS OF ALL AGES WHO ARE STARTED
ON ANTIDEPRESSANT
THERAPY SHOULD BE MONITORED APPROPRIATELY AND OBSERVED CLOSELY FOR
CLINICAL WORSENING,
SUICIDALITY, OR UNUSUAL CHANGES IN BEHAVIOR. FAMILIES AND CAREGIVERS
SHOULD BE ADVISED OF
THE NEED FOR CLOSE OBSERVATION AND COMMUNICATION WITH THE PRESCRIBER.
AMITRIPTYLINE IS NOT
APPROVED FOR USE IN PEDIATRIC PATIENTS. (SEE WARNINGS: CLINICAL
WORSENING AND SUICIDE
RISK, PRECAUTIONS: INFORMATION FOR PATIENTS AND PRECAUTIONS: PEDIATRIC
USE.)
DESCRIPTION
Amitriptyline HCl is 3-(10, 11-dihydro-5_H_-dibenzo [_a,d_]
cycloheptene-5-ylidene)-_N_,_N_-dimethyl-1-
propanamine hydrochloride. Its molecular formula is C
H N • HCl, and its structural formula is:
Amitriptyline HCl, a dibenzocycloheptadiene derivative, has a
molecular weight of 313.87. It is a white,
odorless, crystalline compound which is freely soluble in water.
Each tablet for oral administration contains the following inactive
ingredients: colloidal silicon dioxide,
corn starch, hydroxypropyl cellulose, hypromellose, magnesium
stearate, microcrystalline cellulose,
polyethylene glycol, sodium lauryl sulfate, sodium starch glycolate
and